Acquisition by Bristol Myers Squibb on track to close in the second quarter of 2025: HSR waiting period expired on May 2, 2025; tender offer expected to expire on May 13, 2025 Abecma generated $59 million U.S. commercial revenue in the first quarter of 2025 Ended quarter with approximately $173 million in cash, cash equivalents, and marketable securities CAMBRIDGE, Mass. / May 07, 2025 / Business Wire / 2seventy bio, Inc.... Read More

Entered into definitive merger agreement to be acquired by Bristol Myers Squibb at a price of $5.00 per share in an all-cash transaction; expected to close in the second quarter of 2025 Abecma generated $242 million U.S. sales in 2024 79% reduction in year-over-year net cash spend reflects continued streamlining of cost structure Ended 2024 with approximately $184 million in cash, cash equivalents, and marketable securities... Read More

$5.00 per share, all-cash transaction Expected to close in the second quarter of 2025, subject to customary closing conditions CAMBRIDGE, Mass. / Mar 10, 2025 / Business Wire / 2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE: BMY) (“BMS”) will acquire all of the outstanding shares of 2seventy bio at a price of $5.00 per share in an all-cash transaction... Read More

CAMBRIDGE, Mass. / Feb 25, 2025 / Business Wire / 2seventy bio, Inc. (Nasdaq: TSVT), announced today that members of the management team will participate in a fireside chat at the upcoming TD Cowen 45 th Annual Healthcare Conference on March 5, 2025 at 11:10 a.m. ET in Boston, Mass. A live webcast of the fireside chat will be available via the Investors and Media section of 2seventy bio’s website at... Read More

$242 million in U.S. Abecma sales in 2024 Approximately $184 million of cash, cash equivalents and marketable securities as of December 31, 2024 Net cash burn of $9 million in the fourth quarter of 2024; path to quarterly breakeven by the end of 2025 CAMBRIDGE, Mass. / Feb 06, 2025 / Business Wire / 2seventy bio, Inc. (Nasdaq: TSVT) today provided full-year Abecma® (idecabtagene vicleucel; ide-cel) sales results for 2024, in... Read More

Abecma generated $77 million U.S. commercial revenue, growing 42% versus the second quarter Decision in September to discontinue enrollment in KarMMa-9 study results in over $80 million in anticipated cost savings over the next several years 24% reduction in operating expenses versus the second quarter reflects continued progress on streamlining 2seventy’s cost structure; third quarter net loss of approximately $10 million... Read More

CAMBRIDGE, Mass. / Nov 04, 2024 / Business Wire / 2seventy bio, Inc . (Nasdaq: TSVT) will announce its third quarter 2024 financial results on Tuesday, November 12, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the financial results conference call live via webcast which will be available on the Investors and Media page of the company’s website at https://ir.2seventybio.com.... Read More

2seventy and Bristol Myers Squibb discontinue enrollment in Phase 3 KarMMa-9 study Decision results in over $80 million in anticipated cost savings for 2seventy over the next several years and accelerates path to breakeven in 2025 Expanded 3L+ label drives re-acceleration in Abecma U.S. revenues with third quarter revenue expected to grow approximately 30% from second quarter revenue of $54 million CAMBRIDGE, Mass. / Sep 25,... Read More

CAMBRIDGE, Mass. / Aug 29, 2024 / Business Wire / 2seventy bio, Inc . (Nasdaq: TSVT), announced today that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 22 nd Annual Global Healthcare Conference on September 6, 2024 at 12:20 p.m. ET in New York. A live webcast of the fireside chat will be available via the Investors and Media section of the company’s website at... Read More

Following regulatory approval in the earlier line setting this quarter, Abecma generated $54 million U.S. commercial revenue and saw meaningful growth in demand Recent completion of Hemophilia A and gene editing technology sale to Novo Nordisk for up to $40 million reinforces exclusive focus on Abecma with streamlined cost structure Approximately $28 million (43%) quarter-on-quarter reduction in operating expenses due to... Read More

CAMBRIDGE, Mass. / Aug 05, 2024 / Business Wire / 2seventy bio, Inc . (Nasdaq: TSVT) will announce its second quarter 2024 financial results on Wednesday, August 7, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the conference call live via webcast which will be available on the Investors and Media page of the company’s website at https://ir.2seventybio.com . Participants who wish... Read More

Divestiture Supports Company Focus on Development and Commercialization of Abecma CAMBRIDGE, Mass. / Jun 26, 2024 / Business Wire / 2seventy bio, Inc . (Nasdaq: TSVT), announced today the completion of an asset purchase agreement (“APA”) by Novo Nordisk . Under the terms of the APA, Novo Nordisk has acquired the Hemophilia A program and rights to 2seventy’s in vivo gene editing technology outside of oncology and gene editing... Read More

CAMBRIDGE, Mass. / May 23, 2024 / Business Wire / 2seventy bio, Inc . (Nasdaq: TSVT) announced today that members of the management team will present at the following upcoming investor conferences: TD Cowen 5 th Annual Oncology Innovation Summit: Insights for ASCO & EHA in a virtual fireside chat on Tuesday, May 28, 2024 at 8:30 a.m. ET Goldman Sachs 45 th Annual Global Healthcare Conference in Miami Beach, FL, on Monday,... Read More

U.S. FDA Approval of Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy; Commercial Launch Underway Completion of R&D Pipeline Divestiture to Regeneron Sets Company on Track to Focus Exclusively on Development and Commercialization of Abecma with Streamlined Cost Structure Abecma generated $52 million U.S. commercial revenue in the first quarter of 2024 Ended quarter with... Read More

CAMBRIDGE, Mass. / May 03, 2024 / Business Wire / 2seventy bio, Inc . (Nasdaq: TSVT) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the conference call live via webcast which will be available on the Investors and Media page of the company’s website at https://ir.2seventybio.com . Participants who wish to... Read More

Company Now Exclusively Focused on Development and Commercialization of Abecma CAMBRIDGE, Mass. / Apr 01, 2024 / Business Wire / 2seventy bio, Inc . (Nasdaq: TSVT), announced today the completion of the asset purchase agreement (“APA”) by Regeneron Pharmaceuticals, Inc. Under the terms of the APA, Regeneron has acquired all oncology and autoimmune research and development programs and has hired approximately 160 employees... Read More

CAMBRIDGE, Mass. / Mar 20, 2024 / Business Wire / 2seventy bio, Inc. (Nasdaq: TSVT), announced today that Eli Casdin, Chief Investment Officer, and Founder of Casdin Capital, and Charles Newton, Chief Financial Officer, Lyell Immunopharma, have been appointed as new independent members of the Company’s Board of Directors (the “Board”), effective immediately. Casdin Capital owns approximately 2.3% of 2seventy bio’s... Read More

New strategic path forward as Abecma-focused company announced in January 2024; on track to close Asset Sale of R&D pipeline to Regeneron in the first half of 2024 U.S. Food and Drug Administration Oncologic Drugs Advisory Committee scheduled for March 15, 2024, to review data supporting the supplemental Biologics License Application for Abecma ® (idecabtagene vicleucel) for triple-class exposed relapsed or refractory... Read More

CAMBRIDGE, Mass. / Mar 01, 2024 / Business Wire / 2seventy bio, Inc . (Nasdaq: TSVT) will announce its fourth quarter and full year 2023 financial results on Tuesday, March 5, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Members of the management team will also be presenting at the following upcoming investor conferences: TD Cowen 44 th Annual Healthcare Conference in Boston, MA on Wednesday, March 6,... Read More

CAMBRIDGE, Mass. / Feb 05, 2024 / Business Wire / 2seventy bio, Inc . (Nasdaq: TSVT), announced today that members of the management team will present at the following upcoming investor conferences: Guggenheim Healthcare Talks 6 th Annual Biotechnology Conference, the St. Regis New York, fireside chat on Thursday, February 8 th at 1:30 p.m. ET Citi’s 2024 Virtual Oncology Leadership Summit, Thursday, February 22 nd at 3:00... Read More

Company to focus exclusively on commercialization and development of Abecma, in partnership with Bristol Myers Squibb Company to sell R&D pipeline to Regeneron to launch Regeneron Cell Medicines business led by 2seventy bio’s Chief Scientific Officer, Philip Gregory Chip Baird named incoming Chief Executive Officer; Nick Leschly named incoming Chairman of Board of Directors Expected annual cost savings of approximately $150... Read More

CAMBRIDGE, Mass. / Dec 11, 2023 / Business Wire / 2seventy bio, Inc . (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, announced today that the Company will host a conference call on Tuesday, December 12, 2023, at 8:00am ET. The event will highlight data presented at the 65 th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from December 9-12, 2023, in San Diego. Participants... Read More

CAMBRIDGE, Mass. / Dec 06, 2023 / Business Wire / 2seventy bio, Inc. (NASDAQ: TSVT), (“2seventy” or “the Company”), a leading immuno-oncology cell therapy company, today issued the following statement reiterating its commitment to maximizing shareholder value: As we indicated last month, the Board has commenced a process to consider all options to maximize value. This process is well underway and our team is committed to... Read More

Abecma (idecabtagene vicleucel) data to be presented at ASH 2023; multiple new analyses of KarMMa-3 and KarMMa-2c add to growing body of data supporting the potential safety and efficacy of Abecma in earlier lines of treatment Abecma generated $69 million U.S. commercial revenue in the third quarter of 2023; $302 million U.S. commercial revenue year-to-date Two solid tumor programs positioned to enter clinical trials in 2024... Read More

CAMBRIDGE, Mass. / Nov 10, 2023 / Business Wire / 2seventy bio, Inc . (Nasdaq: TSVT), a leading immune-oncology cell therapy company, will announce its third quarter 2023 financial results on Tuesday, November 14, 2023. 2seventy bio will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide a business update. Participants can access the conference call live via webcast which will be available... Read More

Approximately 40% workforce reduction combined with related actions expected to achieve $130+ million savings in the 2024-2025 period; projected cash runway into at least 2026 to support focus on long-term mission Company to internally advance fewer pipeline programs while expanding collaboration with JW Therapeutics to include new solid tumor and autoimmune programs; Company to gate at-risk investment in bbT369 (NHL) and... Read More

Initial MAGE-A4 T-cell collaboration program set to enter clinic ahead of schedule by end of 2023 Companies plan to add programs in oncology and autoimmune disease to collaboration CAMBRIDGE, Mass. & SHANGHAI, China / Sep 12, 2023 / Business Wire / 2seventy bio, Inc . (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, and JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing... Read More

CAMBRIDGE, Mass. / Sep 06, 2023 / Business Wire / 2seventy bio, Inc . (Nasdaq: TSVT), a leading immune-oncology cell therapy company, announced today that members of the management team will participate in a fireside chat at the upcoming 2023 Morgan Stanley Global Healthcare Conference on September 13, 2023 at 3:35pm ET in New York. A live webcast will be available via the Investors and Media section of 2seventy bio’s... Read More

Abecma (idecabtagene vicleucel) generated $115 million U.S. commercial revenue in 2Q 2023, supporting lower end of U.S. revenue guidance of $470-570 million 2seventy bio provides update on PLAT-08 study in AML with partner Seattle Children’s Ended quarter with $307 million cash, cash equivalents, and marketable securities; maintaining cash runway into 2026 Conference call today at 8:00 AM ET CAMBRIDGE, Mass. / Aug 14, 2023 /... Read More

CAMBRIDGE, Mass. / Aug 08, 2023 / Business Wire / 2seventy bio, Inc . (Nasdaq: TSVT), a leading immune-oncology cell therapy company, will announce its second quarter 2023 financial results on Monday, August 14, 2023. 2seventy bio will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide a business update. Participants can access the conference call live via webcast which will be available on... Read More

CAMBRIDGE, Mass. / Aug 01, 2023 / Business Wire / 2seventy bio, Inc . (Nasdaq: TSVT), a leading immune-oncology cell therapy company, announced today that members of the management team will present at the upcoming 2023 Wedbush PacGrow Healthcare Conference on August 8, 2023 at 8:00am ET in New York. About 2seventy bio Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to... Read More

CAMBRIDGE, Mass. / Jun 14, 2023 / Business Wire / 2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today announced that the Phase 1 trial of the PLAT-08 study of SC-DARIC33 in Acute Myeloid Leukemia (AML) has been paused by Seattle Children’s, the Company’s partner and the regulatory sponsor of the study. The pause was instituted as part of the clinical study protocol stopping rules in... Read More

CAMBRIDGE, Mass. / Jun 07, 2023 / Business Wire / 2seventy bio, Inc . (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, announced today that members of the management team will participate in a fireside chat at the upcoming Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023 at 6:20pm ET in Dana Point, CA. A live webcast will be available via the Investors and Media section of... Read More

Results of preliminary correlative analysis from the PLAT-08 study show rapamycin-regulated in vivo expansion and activation of SC-DARIC33 T cells as well as concurrent anti-CD33 activity Enhanced anti-acute myeloid leukemia (AML) potency was obtained with the combination of regulated IL-15 production combined with rapamycin-controlled DARIC33 activation – a potential next generation approach SC-DARIC33 is a potentially... Read More

bbT369, a dual-targeted (CD79a/CD20) and CBLB gene edited autologous CAR T for non-Hodgkin lymphoma, showed edit-driven enhanced T cell activity in multiple preclinical models RESET, a novel TCR coupled antigen receptor architecture, displayed markedly increased targeting sensitivity and pharmacologically controlled anti-tumor activity A novel TGFβ switch receptor drove enhanced MAGE-A4 TCR anti-tumor activity with a... Read More

Subgroup analysis of outcomes for patients with high-risk relapsed and refractory multiple myeloma (RRMM) from the pivotal Phase 3 KarMMa-3 trial accepted for oral presentation at EHA Analysis from KarMMa-3 study of health-related quality of life in patients who received Abecma will be presented at ASCO Breadth of data underscores 2seventy bio’s commitment to meeting the individual needs of patients with RRMM or newly... Read More

Abecma (idecabtagene vicleucel) generated $118 million U.S. commercial revenue in 1Q 2023, supporting upper end of U.S. revenue guidance of $470-570 million U.S. FDA accepted supplemental Biologics License Application (sBLA) based on results from the pivotal phase 3 KarMMa-3 study of Abecma; PDUFA date December 16, 2023 Collaboration with Novo Nordisk delivers proof of concept data for in-vivo gene editing hemophilia A... Read More

Late-breaking oral presentation will show early findings from Phase I PLAT-08 study of SC-DARIC33, an investigational, potentially first-in-class CD33-targeting CAR T in pediatric and young adults with relapsed/refractory acute myeloid leukemia (AML) Updates on the Company’s portfolio include investigational therapies in AML, non-Hodgkin lymphoma (NHL) and solid tumors CAMBRIDGE, Mass. / May 02, 2023 / Business Wire /... Read More

2seventy bio plans to present data at virtual Research and Development deep dive on May 19, 2023 CAMBRIDGE, Mass. / May 01, 2023 / Business Wire / 2seventy bio, Inc. (Nasdaq: TSVT) a leading immuno-oncology cell therapy company, today announced that it has achieved a preclinical $15 million milestone as part of the joint research and development collaboration focused on an in vivo gene editing treatment for hemophilia A. The... Read More

CAMBRIDGE, Mass. / Apr 28, 2023 / Business Wire / 2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, will announce its first quarter 2023 financial results on Wednesday, May 3, 2023. 2seventy bio will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a business update. Participants can access the conference call live via webcast which will be available on... Read More

CAMBRIDGE, Mass. / Mar 16, 2023 / Business Wire / 2seventy bio, Inc . (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today reported financial results and recent highlights for the fourth quarter and full year ended December 31, 2022. “In our first full year of operations, 2seventy made tremendous strides across all aspects of our business: from advancing early-stage research, building out manufacturing... Read More

CAMBRIDGE, Mass. / Mar 08, 2023 / Business Wire / 2seventy bio, Inc. (Nasdaq: TSVT) today announced the appointment of Wei Lin, M.D. to the company’s Board of Directors, effective immediately. “We are thrilled to welcome Dr. Wei Lin to 2seventy’s Board during an exciting time in our Company’s growth,” said Nick Leschly, chief kairos officer. “Wei’s leadership and deep expertise in clinical development strategy for cancer... Read More

CAMBRIDGE, Mass. / Mar 03, 2023 / Business Wire / 2seventy bio, Inc . (Nasdaq: TSVT) announced today that members of the management team will present at the 43rd Annual TD Cowen Health Care Conference at the Boston Marriott Copley Place in Boston, MA on March 7, 2023 at 10:30am ET. A live webcast will be available via the Investors and Media section of 2seventy bio’s website at https://ir.2seventybio.com/ . A replay will be... Read More

CAMBRIDGE, Mass. , March 1, 2023 /PRNewswire/ -- Marengo Therapeutics, Inc., a company pioneering novel immuno-therapeutics targeting the T cell receptor (TCR) Vβ to selectively activate the right T cell subsets to fight cancer, today announced the appointment of Kevin Chin , M.D., M.S., as Chief Medical Officer. Dr. Chin is a seasoned oncology clinical development expert in T cell directed immunotherapies with a proven... Read More

CAMBRIDGE, Mass. / Feb 28, 2023 / Business Wire / 2seventy bio, Inc. (“2seventy bio”) (Nasdaq: TSVT), a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer, announced today the pricing of a follow on underwritten public offering of 10,869,566 shares of its common stock at a public offering price of $11.50 per share. All of the shares in the... Read More

Milestone payment is related to the establishment of 2seventy bio’s strategic partnership with JW Therapeutics Payment provides further validation of Medigene’s end-to-end platform MARTINSRIED, Germany and MUNICH, Germany, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Martinsried -- Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology company focused on the development of differentiated, best-in-class T Cell Receptor... Read More

Anticipate $470-$570M topline U.S. revenue Abecma (idecabtagene vicleucel) in 2023, shared equally with Bristol Myers Squibb (BMS) KarMMa-3 data to be presented at EBMT-EHA 5 th European CAR T-cell Meeting on February 10, 2023; 3L+ sBLA submission for Abecma targeted completion in Q1 Expanded translational collaboration with Regeneron to explore and fund cell therapy combinations in solid tumors Enrollment progress across... Read More

Collaboration Leverages 2seventy's Platform for T Cell Therapy Research and Development with Regeneron Antibodies and Bispecifics to Explore Multiplex Combination Approaches Regeneron Investing $20 million in 2seventy Equity; Regeneron to Fund 100% of Clinical Development Costs for Regeneron-Based Combination Clinical Trial Arms Through Approval 2seventy bio, Inc. (Nasdaq: TSVT) today announced an amendment to its... Read More